Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID-2019 immune globulins (Equine) - Emergent BioSolutions

Drug Profile

COVID-2019 immune globulins (Equine) - Emergent BioSolutions

Alternative Names: Anti-SARS-CoV-2 immune globulin intravenous (Equine); COVID-19 immune globulins (Equine); COVID-EIG

Latest Information Update: 29 May 2020

At a glance

  • Originator Emergent BioSolutions
  • Class Antivirals; Immunoglobulin fragments
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 29 May 2020 Preclinical trials in COVID-2019 infections in USA (Parenteral), prior to May 2020 (Emergent BioSolutions pipeline, May 2020)
  • 11 Mar 2020 Emergent BioSolutions plans a clinical trial for COVID-2019 infections (Parenteral), in the third quarter of 2020
  • 11 Mar 2020 Early research in COVID-2019 infections in USA (Parenteral)

Development Overview

Introduction

Equine-derived purified immune globulin fragments, derived from polyclonal antibodies, designated as COVID EIG, is being developed by Emergent BioSolutions, for the treatment of severe COVID-2019 infections. The company has utilised its hyperimmune platform which allows the isolation of purified immune globulin fragments from polyclonal antibodies which are specific for SARS-CoV-2 antigens from immunised horses. Hyperimmunes are polyclonal antibody therapeutics derived from plasma that leverage the immune response in humans and can provide protection from the infection. Preclinical development is underway in the US.

Key Development Milestones

As of May 2020, Emergent BioSolutions is conducting preclinical trials for the treatment of severe COVID-2019 infections (Emergent BioSolutions pipeline, May 2020).

In March 2020, Emergent BioSolutions reported initiation of plasma collection from horses in order to isolate and manufacture antibodies against SARS-CoV-2 virus [1] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Antivirals, Immunoglobulin fragments
  • Mechanism of Action Immunomodulators
  • WHO ATC code

    J06B (Immunoglobulins)

  • EPhMRA code

    J6H (Specific Immunoglobulins - Antiviral)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Preclinical USA Parenteral / unspecified Emergent BioSolutions 29 May 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Emergent BioSolutions Originator USA
Emergent BioSolutions Owner USA

Future Events

Expected Date Event Type Description Updated
30 Sep 2020 Trial Update Emergent BioSolutions plans a clinical trial for COVID-2019 infections (Parenteral), in the third quarter of 2020 [1] 29 May 2020

Development History

Event Date Update Type Comment
29 May 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections in USA (Parenteral), prior to May 2020 (Emergent BioSolutions pipeline, May 2020) Updated 29 May 2020
11 Mar 2020 Trial Update Emergent BioSolutions plans a clinical trial for COVID-2019 infections (Parenteral), in the third quarter of 2020 [1] Updated 29 May 2020
11 Mar 2020 Phase Change Early research in COVID-2019 infections in USA (Parenteral) [1] Updated 19 Mar 2020

References

  1. Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease.

    Media Release
Back to top